Sitagliptin Use in Patients with Chronic Kidney Disease

Introduction to Sitagliptin Therapy

The American College of Cardiology and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend sitagliptin as a third-line agent for glycemic control in patients with type 2 diabetes and chronic kidney disease (CKD), with a treatment hierarchy that prioritizes metformin plus SGLT2 inhibitors as first-line therapy, followed by GLP-1 receptor agonists as second-line therapy 1, 2, 3

The KDIGO 2022 guidelines establish a clear hierarchy for the treatment of type 2 diabetes in patients with CKD, with metformin plus SGLT2 inhibitors as first-line therapy for patients with an estimated glomerular filtration rate (eGFR) of 30 ml/min per 1.73 m² or higher, GLP-1 receptor agonists as second-line therapy, and DPP-4 inhibitors like sitagliptin as third-line therapy 1, 2, 3
The National Kidney Foundation recommends that SGLT2 inhibitors and GLP-1 receptor agonists be prioritized over sitagliptin due to their proven cardiovascular and renal protection benefits, whereas sitagliptin has demonstrated cardiovascular safety but no cardiovascular benefit in the TECOS trial 4, 5

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend strict dose reduction of sitagliptin based on kidney function, with a dosing algorithm that includes 100 mg once daily for patients with an eGFR of 45 ml/min per 1.73 m² or higher, 50 mg once daily for patients with an eGFR of 30-44 ml/min per 1.73 m², 25 mg once daily for patients with an eGFR of 15-29 ml/min per 1.73 m², and 25 mg once daily for patients with an eGFR below 15 ml/min per 1.73 m² or those on dialysis 4, 5
The American Diabetes Association recommends monitoring eGFR at least every 3-6 months and adjusting sitagliptin dose immediately if kidney function declines, with more frequent monitoring warranted in patients with rapidly declining kidney function or acute illness 4, 5

The European Association for the Study of Diabetes recommends linagliptin as a preferred DPP-4 inhibitor alternative in CKD due to its simplified dosing regimen, which requires no dose adjustment regardless of kidney function, with a constant 5 mg once daily dose even in severe renal impairment (eGFR below 30) and dialysis 4, 5
The International Society of Nephrology recommends choosing linagliptin over sitagliptin when simplifying medication regimens to reduce dosing errors, when kidney function is unstable or rapidly declining, or when patient adherence to complex dosing is a concern 4, 5

The National Kidney Foundation warns against common prescribing errors that compromise patient safety, including failure to dose-adjust sitagliptin, using sitagliptin as first-line therapy in high-risk CKD patients, continuing metformin inappropriately, and combining sitagliptin with sulfonylureas without counseling 1, 2, 3, 4, 5

The American College of Cardiology recommends reassessing HbA1c within 3 months of initiating sitagliptin to determine if glycemic targets are achieved, with intensification of therapy with GLP-1 receptor agonist or insulin rather than increasing sitagliptin dose beyond recommended limits if targets are not met 1, 2, 3, 4, 5